Studies related to Liver Enzymes and Coenzyme Q10

Coenzyme Q10 Administration Has No Effect On SICAM-1 And Metabolic Parameters Of Pediatrics With Type 1 Diabetes Mellitus

Effect None
Values μkat/L. AST. Mean and SD. Baseline (for all): 0.52 ± 0.23 Control: 0.54 ± 0.19 Omega-3: 0.38 ± 0.13 Omega-3-COQ10: 0.41 ± 0.12 ALT Baseline (for all): 0.61 ± 0.32 Control: 0.59 ± 0.24 Omega-3: 0.41 ± 0.14 Omega-3-COQ10: 0.51 ±  0.34 GMT. Baseline (for all): 0.42 ± 0.24 Control: 0.49 ± 0.28 Omega-3: 0.52 ± 0.39 Omega-3-COQ10: 0.51 ± 0.32 ALP Baseline (for all): 0.98 ± 0.32 Control: 0.87 ± 0.39 Omega-3: 0.87 ± 0.39 Omega-3-COQ10: 0.65 ± 0.29
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 105
Sex Both Genders
Notes for this study:
In a randomized, double-blind, controlled trial, 105 participants with dyslipidemia and elevated triglycerides who were taking statins were allocated to take 2.52 g of PUFA or PUFA with 200 mg of coenzyme q10 daily, or no intervention and continued their normal medication for 3 months.

There were no statistically significant differences between the PUFA group and the PUFA + Coenzyme q10 group besides a greater reduction in total cholesterol in the latter group. (Nonsignificant findings can be found in the values boxes of their respective entries).